Table 2.
Immune-adaptive prevalent (IA-P) | Immune-innate prevalent (IN-P) | ||||
Hydrocortisone | Placebo | Hydrocortisone | Placebo | Interaction P | |
VANISH TRIAL | |||||
n | 30 | 34 | 28 | 25 | |
28-day mortality (%) | 43.3 | 14.7 | 32.1 | 40 | 0.028 |
BURN trial | |||||
n | 7 | 8 | 8 | 7 | |
28-day mortality (%) | 57.1 | 0.0 | 25 | 28.6 | 0.99 |